Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So 3 sold out so this may be a new low
Chinese aren't only ones buying..check out institutional activity !!
https://www.nasdaq.com/symbol/casi/institutional-holdings
Accurate
After hours..... OVER $4 ..
SEC FILING HE-WU...
Just a wild guess, Celgene has some issues with their proprietary drugs re possible generics coming in soon. Why not market their drugs in China thru a company they already have an interest in......GUESS WHO ? What company has gotten in the door in China ? You Guess ! Well that's my guess.....
ACCURATE
Multi year CASI closing high yesterday !!
Plus traded up after hours.
Must be a reason !
Accurate
Hong Kong Firm now owns almost 10% of CASI.
https://www.sec.gov/Archives/edgar/data/895051/000114420417061957/tv480649_sc13g.htm
The Chinese are accumulating because they know something we don't !
Accurate
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
ROCKVILLE, Md., Dec. 1, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the 2017 San Antonio Breast Cancer SymposiumTM (SABCS), December 5-9, 2017 in San Antonio, Texas.
ENMD-2076 is currently in a Phase 2 trial for the treatment of triple-negative breast cancer (TNBC) at two locations in the U.S. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website after the conclusion of the presentation.
Program Number: PD3-16
Abstract Number: 272
Session Title: Novel Drugs / Predicting Response for HER2+ Breast Cancer
Session Date: Thursday, December 7, 2017
Session Time: 7:00:00 AM – 9:00:00 AM CST
Title: "Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer"
CASI short interest 11/15 up to 622,000 from 259,000.
Highest I can remember 1
All that shorting and it's still in an uptrend.
What if they HAVE to cover ?
Accurate
Vanguard Group added 71,000 shares (25% increase) before 9/30.
I would bet some other funds added a lot more in October/November.
Accurate
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
ROCKVILLE, Md., Nov. 14, 2017 - CASI Pharmaceuticals, Inc. (the “Company”) (CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and nine months ended September 30, 2017.
As of September 30, 2017, CASI had cash and cash equivalents of approximately $21.6 million.
CASI reported a net loss for the third quarter of 2017 of ($1.6 million), or ($0.03) per share. This compares with a net loss of ($1.7 million), or ($0.03) per share, for the same period last year. For the first nine months of 2017, the Company reported a net loss of ($5.7 million), or ($0.10)per share as compared to a net loss of ($6.8 million), or ($0.15) per share for the first nine months of 2016. The smaller net loss for the nine-month period in 2017 can be attributed to a decrease in non-cash compensation expense associated with the timing of stock option issuances and a decrease in clinical costs associated with the ENMD-2076 fibrolamellar trial, offset by an increase in R&D costs related to the advancement of EVOMELA®, MARQIBO®, and ZEVALIN® with the China Food and Drug Administration (CFDA) and an increase in costs related to our internal preclinical program.
Ken K. Ren, Ph.D., CASI’s Chief Executive Officer, stated, “I am pleased with our third quarter financial results. In October, we announced a $23.8 million registered direct offering, funds raised from which will be used to advance our internal pipeline and support our business development in-license activities. With respect to existing in-licensed assets, we continue to advance EVOMELA®, MARQIBO®, and ZEVALIN® for the China market. EVOMELA® has been granted priority review by the CFDA, which we believe will accelerate its approval for the treatment of patients with multiple myeloma. We look forward to providing further updates on these in-licensed assets as well as on our internal pipeline candidates.”
So far, So good !
Accurate
May the Bands that you refer to, play sweet music!
Bollinger Bands are tightening on CASI...
Take a look at what happened the last time that happened a little over a month ago.
Accurate
I have been waiting since the 1990's. I'm now as hopeful and enthusiastic as ever. I am not an expert on stock trading, but I have never seen the volume (accumulation?) that I am seeing now before. I think I may remember one day of a million volume with Entremed but every single good day was always followed by many disappointing down days. Every seemingly good news story was always followed by drops in stock price--for over two decades! Still waiting for the news that will actually make this stock rise.
Rocky I
accurate, yes it's been a very long wait! thanks for your opinion. always appreciated!
Hi Tomas,
Yes the accumulation is taking place. I watched the trades for several hours yesterday. Very odd 100 share trades at 2.54.99 then 2.55.99 etc. You and I don't do 100 share trades for hours at a price ending in .99 (100th of a cent below an even number}They accumulated thousands of shares buying 4 or 5 hundred a minute. 10 minutes or a little less before the close they went to 1000 shares a trade at .99/100.
Then a rush by them and or others just before the close to pick up the thousands of shares built up at a limit sell price at the morning high of 2.60, then step back in the last minute to let the price settle.
Chart says up Volume says up.
Been a long wait.
Oh also there have been a couple additional research firms to write up CASI.
Good Luck !
Accurate
accurate, I see you're still following ENMD! looks like a lot of accumulation going on. would like to hear your opinion.
Regarding the previous post:
What you are missing is at least 2 fold.
First CASI has it's own drugs in Clinical trials, 2076 shows good promise in a couple of cancer types.
More recently the question is why did they raise another 20+ Million $ ?
Consider this as a possibility: They have established a working relation with the Chinese. Wouldn't you find ways to get more drugs to market in addition to the 3 you mentioned ?
Put another way if you had drugs approved here wouldn't you want CASI to market them to the country with the biggest population. Guess who has the inside track on that !
In addition they got the Chinese to agree to include tests done in this country on drugs already approved here in their determination to approve there. Speeds thing up considerably.
Accurate
I really don't understand what all the excitement is with this company? The latest presentation by CASI management state all 3 combined drugs will provide peak annual sales of only $148M. The closest drug to actually being sold is Evomela and that isn't until Q4 2019 and will provide peak sales of only $35M. While this is all good news it does not translate into a lot of revenue to greatly propel the share price. I admit I'm new to the stock so I'm no expert here. I really like the idea of them using their contacts within China to not only sell product but also provide low cost manufacturing but the total peak revenues are nothing to write home about. What am I missing here? Perhaps this is more of a very long term hold as I like their strategy of being the next Celgene in China........but they have a long long way to go...... Maybe this is more of a ten year hold as I don't see enough in the pipeline to generate at least $500M to $1B in annual peak sales......at least not according to their own presentation. It is encouraging to see large insider buys;this adds to my conundrum regarding investing strongly in the company.
I appreciate if anyone can shed any light on the aforementioned issues I have stated. Perhaps I messed up on some points of data?
Key FDA Approvals Paramount Catalyst for Biotech Run Heading Into November
Tuesday 10/31/2017 08:45 AM ET - PR Newswire via Dow Jones News
MarketNewsUpdates.com News Commentary PALM BEACH, Florida, October 31, 2017 /PRNewswire/ -- The FDA has approved 34 drugs to date in 2017 after approving 22 novel drugs last year. Many biotech and pharma companies have dealt with the drug development process being lengthy and time-consuming along with requiring the utilization of a lot of funds and resources while key drug development events including trial data and regulatory updates are of great importance and could act as major catalysts going forward. Active Biotech stocks are in position to close an already strong 2017 with a bang as the FDA gets set to approve additional drugs heading into next month. Notable biotech leaders in the headlines include: Citius Pharmaceuticals Inc. (NASDAQ: CTXR), MannKind Corporation (NASDAQ: MNKD), Akari Therapeutics Plc (NASDAQ: AKTX), Endocyte Inc. (NASDAQ: ECYT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS)
The Chairman has bought almost 1 million shares as an insider over the last two months. Does that say anything about this stock?
Wei-Wu He, Ph.D., Chairman
Dr. He has been a Director of the Company and was appointed Executive Chairman in February 2012. Dr. He is currently the CEO and Chairman of OriGene Technologies, Inc. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 20 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents.
CASI Pharmaceuticals press release
View this email in your browser
CASI PHARMACEUTICALS ANNOUNCES $23.8 MILLION REGISTERED DIRECT OFFERING LED BY EXISTING SHAREHOLDERS
ROCKVILLE, Md. (October 13, 2017) – CASI Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced that it has entered into definitive agreements with certain institutional and accredited investors, including existing shareholders, to purchase approximately $23.8 million of securities in a registered direct offering. CASI expects to receive net proceeds of approximately $23.3 million after deducting agent’s fees and other offering expenses.
CASI has agreed to sell an aggregate of approximately 7,951,868 shares of its common stock and warrants to purchase shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.2 share of common stock will be sold for a purchase price of $3.00. The warrants will become exercisable six months after the issuance date and have a term of 2.5 years and an exercise price equal to $3.75. The offering is expected to close on or about October 17, 2017, subject to satisfaction of customary closing conditions.
Dr. Wei-Wu He, the Company’s Chairman, stated, ‘We are pleased with the return of our investors and the positive momentum of our Company. We intend to use the net proceeds to support our business development activities and drive the Company’s continued growth. We also are pleased with the China FDA’s recent public guidance that in its efforts to accelerate approvals for imported drugs, it plans to accept data from clinical trials outside of China. We believe this could potentially accelerate our pipeline of U.S. approved drugs that are currently under China FDA review, namely EVOMELA®, which has been granted priority review; and MARQIBO® and ZEVALIN®. We look forward to accelerating these medicines to the second largest pharmaceutical market, and will continue to add on to our pipeline.”
HC Wainwright acted as exclusive placement agent in this transaction. A shelf registration statement containing a prospectus relating to the shares of common stock and warrants to be issued in this transaction (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 15, 2015. A prospectus supplement relating to the offering will be filed by CASI with the SEC. Copies of the prospectus and prospectus supplement and accompanying prospectuses may be obtained directly from. This announcement is neither an offer to sell nor a solicitation of an offer to buy any securities of CASI. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About CASI Pharmaceuticals, Inc.
CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI’s product pipeline features (1) EVOMELA®, MARQIBO® and ZEVALIN®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory and clinical process for market approval in China, (2) CASI-001 and CASI-002, proprietary preclinical candidates in immune-oncology, and (3) our proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in CASI’s filings with the U.S. Securities and Exchange Commission.
CASI’s China rights to EVOMELA® (melphalan) for Injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and ZEVALIN® (ibritumomab tiuxetan) were previously licensed from its partner Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA’s approval of these three licensed products, CASI is pursuing the Import Drug registration path for approval in China.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
EVOMELA®, MARQIBO® and ZEVALIN® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.
COMPANY CONTACT:
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com
INVESTOR CONTACT:
Torrey Hills Capital
Jim Macdonald
858.456.7300
jm@sdthc.com
Copyright © 2017 CASI Pharmaceuticals, Inc., All rights reserved.
You are receiving this email because you requested to receive press releases via email at our website, casipharmaceuticals.com (formerly entremed.com).
Our mailing address is:
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300Rockville, MD 20850
Add us to your address book
unsubscribe from this list
update subscription preferences
Maybe just a sell on news thing. The way i read it 23.8mm/8mm is 2.975 a share $CASI
Market surely didn't like this morning's PR. I really didn't see an issue with it other that the PPS seemed very low for the exercisable shares.
Banked cash? So you sold this before the amazing secret news you have hits?
yeah you are right.
As I admire my banked cash tonight over dinner.
Nothing
"not at liberty" ...you stock promoters are too funny. You know nothing!!!!
Not at liberty to discuss or speculate
Casi is undergoing some significant growth
People are recognizing the potential
Next few weeks will tell the tale
You asked if we wanted to know... Well, other than the under-the-surface reason, what are the other apparent reasons. I have a considerable amount of Quid tied up into CASI. I know the reasons I like it, but since you offered, I would really like to know what you are seeing...
You will have to wait and watch
Don't mess with Chinese business men like wu
He controls the near term destiny of Casi
Please enlighten us on your analysis Dr J.
Opened a little position just now at 3.55
Good luck toa ll
do you want to know the real reason casi is running wild
there are 3 exactly
2 are obvious
the third is below the surface
You may hear next week of this last one
CASI is acting just like it did yesterday premarket slight gap up then KABOOM on yesterdays open we ran up over 100% fast. Hoping to do the same today!
There is a lot of big CASI news forthcoming. This is the time to be loading when insiders have been buying for weeks now! CASI could be a $10.00 to $20.00 dollar plus stock very soon!
CASI Provides Pipeline Development Update
ROCKVILLE, Md., Sept. 7, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today provided an update to its pipeline.
EVOMELA®:
China’s Food and Drug Administration (CFDA) has granted priority review for CASI’s import drug registration clinical trial application for EVOMELA (melphalan) for Injection. The CFDA cited the following three reasons for granting the priority review:
EVOMELA is indicated for the treatment of multiple myeloma, which is classified as a rare disease in China;
There is no melphalan in any formulation available in China to address this unmet medical need;
EVOMELA has clear therapeutic advantages to currently available therapeutics.
MARQIBO® and ZEVALIN®:
The CFDA review of CASI’s MARQIBO import drug clinical trial application (CTA) is in process. The Company anticipates that the CFDA will complete its review of the CTA in the next four to six months, and expects to initiate the confirmatory trial within six months after CTA approval. The confirmatory trial is required as part of the registration process for the import drug registration.
The CFDA filing and review of CASI’s ZEVALIN import drug clinical trial application (CTA) is in process. The ZEVALIN antibody kit and the radioactive Yttrium-90 component of the clinical trial application require separate submissions to the CFDA, which the first part is currently under review and the latter part is in the submission process. The Company expects to initiate the confirmatory trial within six months after the CFDA’s approval of both the ZEVALIN kit and the Yttrium-90 submissions.
Ken Ren, Ph.D., CASI’s Chief Executive Officer, commented, “We are pleased that the CFDA in granting priority review for EVOMELA has recognized the superior therapeutic advantages of EVOMELA to address the urgent unmet medical need in the rare disease of multiple myeloma in China. Melphalan is extensively used worldwide in the treatment of patients with multiple myeloma, however, no formulation of melphalan is currently available in China. We appreciate the CFDA opening this accelerated pathway for this critical medicine to reach patients in China; it also is a positive signal from the CFDA to accelerate the import drug registration process for U.S. FDA approved drugs in order to address the significant unmet medical needs of the Chinese population in an accelerated time frame. We also are pleased with the progress of MARQIBO and ZEVALIN and are looking forward to their continued advancement in the import drug registration process.”
ENMD-2076:
Dr. Alex Zukiwski, M.D, CASI’s Chief Medical Officer, commented, “ENMD-2076 has been investigated in a number of tumor types based on the known mechanism of action and the oncogenic pathways of the specific malignancy. Although anticancer activity was observed in the clear cell ovarian carcinoma and soft tissue sarcoma studies, the level of single agent activity does not support the development of ENMD-2076 in these two tumor types as a monotherapy. We look forward to providing an update on the ENMD-2076 Triple Negative Breast Cancer and Fibrolamellar Carcinoma data in the next few months.”
Clear Cell Ovarian Carcinoma (CCOC) and Soft Tissue Sarcoma (STS). The data from the investigator-sponsored Phase 2 study in patients with CCOC was presented at the 2017 Annual Meeting of the American Society of Clinical Oncology. The data from the investigator-sponsored Phase 2 study in patients with STS was presented at the 2015 Annual Meeting of the Connective Tissue Oncology Society. The correlative genomics testing has been completed and a publication is expected to be submitted in 2017. Based on the clinical data, CASI has determined it will not pursue company sponsored development of ENMD-2076 in CCOC and STS.
Triple Negative Breast Cancer (TNBC). The accrual to the investigator sponsored Phase 2 study in patients with previously treated advanced and metastatic TNBC is complete and the correlative biomarker/genomics analysis is ongoing. The data will be presented at the 2017 San Antonio Breast Cancer Symposium.
Fibrolamellar Carcinoma (FLC). The accrual to this ongoing Phase 2 study is complete and is in the follow up phase. It is anticipated that the data from this study will be submitted to a medical conference for presentation in 2018.
Still time to get in, because we will likely have GREEN days the remainder of this week.
I was either going to buy this or $ath. X .... today I made the wrong decision. Ah well... live and learn.
CASI ran over 100% this AM on insider buys that hit afterhours yesterday. Another form 4 hit afterhours today and we expect more in the days ahead so if we do what we did this AM CASI could see $7.00 tomorrow. We almost hit $5.00 this AM!
Correction to my last post:
Another CASI SEC form 4 for insider buying just showed up afterhours. See everyone over $5.00 and $6.00 or even $7.00 tomorrow IMO as we ran over 100% with ease this AM from yesterdays 10$ filing! If we run tomorrow like we did today CASI should see $7.00. I knew all this volume and buying meant something. We have had several insider buys hitting in the past days and last Oct. they were massive so get ready for more ahead. I said it just before this latest one hit! I love it. Sellers will be crying and shorts will be frying. This AM we ran to $4.84 and CASI was up over 100% from the form 4 that hit yesterday. Tomorrow is going to get insane. Watch for lot's more form 4's to hit going forward, the insiders bought 1.8 million shares approx. last Oct. This Nov. we are expecting big news also! CASI could be over $10.00 soon!
JMO
Another CASI SEC form 4 for insider buying just showed up afterhours. See everyone over $5.00 and $6.00 or even $7.00 tomorrow IMO as we ran over 100% with ease this AM from yesterdays 10$ filing! I knew all this volume and buying meant something. We have had several insider buys hitting in the past days and last Oct. they were massive so get ready for more ahead. I said it just before this latest one hit! I love it. Sellers will be crying and shorts will be frying. This AM we ran over $2.50 on the one that hit yesterday early this AM. Tomorrow is going to get insane. Watch for lot's more to hit going forward the insiders bought 1.8 million shares approx. last Oct. Nov. we are expecting big news also! CASI could be over $10.00 soon!
Remember we had this talk last month and look what the PPS has done since then. You mentioned moving above $6.00 in Nov. I think we will do it sooner based on todays trading action! I do not see a day like today anywhere on the charts going way back with this insane volume. Something big is up ahead IMO. If we easily ran to $4.84 today imagine how huge we can run just ahead! Holding all my CASI shares tight. I also noticed last years massive insider buys of almost 1.8 million shares were in Oct. I would not be surprised to see more of them in the days ahead.
* * $CASI Video Chart 10-11-17 * *
Link to Video - click here to watch the technical chart video
What a day here? continuation tomorrow?
Look at the insider CASI buys in the past year. The recent massive insider buys are at a higher PPS on the charts, also insiders made 2 massive purchases of almost 2 million shares each in the month of Oct. 2016 totaling approx. 3.8 million shares. Some big $$$ was also loading big today. This AM the volume was massive to $4.84 almost $5.00. I am betting we will be over $5.00 and $6.00 very soon. Heck it could happen tomorrow for the $5.00 break since we almost did that one earlier this AM. There have been ZERO insider sells only lot's of buys. I loved how easy we ran up a couple dollars above this AM with ease. If we do the same or similar tomorrow we will be over $5.00 and looking towards $6.00.
JMO
Insiders have been buying lot's of CASI shares. See everyone over $5.00 ahead. Low float so this one runs easy. Plus we hit $4.84 easy this AM. The $5.00 break is next IMO.
Followers
|
23
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
287
|
Created
|
06/16/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |